Altimmune (ALT) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Altimmune is the larger company by market cap ($505.7 million vs $497.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | MPLT |
|---|---|---|
| Share price | $2.60 | $8.95 |
| Market cap | $505.75M | $497.40M |
| 1-day change | 0.00% | -2.19% |
| YTD return | -27.98% | -47.91% |
| 1-year return | -33.84% | — |
| 5-year return | -78.35% | — |
| EPS (TTM) | $-0.76 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $40.43 |
| 52-week low | $2.55 | $8.89 |
| Distance from 52-week high | -59.63% | -77.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +558.08% | +196.54% |
| Average volume | 4.21M | 851.70K |
| Shares outstanding | 194.52M | 52.85M |
| Employees | 57 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
ALT vs MPLT FAQ
Which is bigger, Altimmune or MapLight Therapeutics?
Altimmune (ALT) is larger, with a market capitalization of $505.75M compared with $497.40M for MapLight Therapeutics (MPLT).
Are Altimmune and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.